Innovative Hemophilia Treatments Offer Hope Amid Lingering Clinical Challenges
HCPLive
DECEMBER 8, 2024
At ASH 2024, Annette von Drygalski, MD, PharmD, described the paradigm shift that has taken place in hemophilia over the past decade.
Sun.Dec 08, 2024
102 
GLP-1 Receptor Agonists Could Reduce Stroke Risk in Type 2 Diabetes
HCPLive
DECEMBER 8, 2024
A propensity score-matched study from ASH 2024 suggests GLP-1 RA use reduced VTE risk in type 2 diabetes.
My video interview with Connie Jorsvik: The “Patient Pathways” workshop
Heart Sisters
DECEMBER 8, 2024
"When Connie Jorsvik was a cardiac nurse, it always seemed like more women than men were admitted to her hospital after Christmas. Many of these women had been experiencing cardiac symptoms for days - and even weeks. Women tend to put off seeking treatment because we so often put ourselves last on our priority list - and there is no bigger time for everyone else's priorities than the holidays!
Caroline Piatek, MD: Improving Patient-Reported Outcomes in PNH With Danicopan Add-on Therapy
HCPLive
DECEMBER 8, 2024
Piatek shared the latest data update from the phase 3 ALPHA study at the ASH 2024.
Cardiology MCQ: Echo Basics
All About Cardiovascular System and Disorders
DECEMBER 8, 2024
Adult transthoracic echocardiography uses frequencies in the range of: A. 1-2 MHz B. 2.5-5 MHz C. 5.5-6.5 MHz D. 7-10 MHz Correct answer: B. 2.5-5 MHz Higher frequency like 7-10 MHz can be used in pediatric imaging and in transesophageal echocardiography. Higher frequencies give better resolution, but penetration is poor. In an adult where the cardiac structures are at a higher distance for transthoracic echocardiography, lower frequency is preferred.
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
HCPLive
DECEMBER 8, 2024
Frangoul discussed highlights from the latest data update from the CLIMB SCD-121 trial of Casgevy.
Sign up to get articles personalized to your interests!
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
More Trending
Universal 25 µg/L Threshold for Iron Deficiency is Cost-Effective, Could Improve Management in US Women
HCPLive
DECEMBER 8, 2024
Yale study at ASH 2024 finds screening adult women for iron deficiency with a ferritin threshold of 25 g/L is cost-effective.
Trends in sepsis-associated cardiovascular disease mortality in the United States, 1999 to 2022
Frontiers in Cardiovascular Medicine
DECEMBER 8, 2024
PurposeCardiovascular disease (CVD) is the leading cause of death in the United States, and sepsis significantly contributes to hospitalization and mortality. This study aims to assess the trends of sepsis-associated CVD mortality rates and variations in mortality based on demographics and regions in the US.MethodsThe Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database was used to identify CVD and sepsis-related deaths from 1999 to
Eltrombopag Bests Standard of Care as First-Line Therapy in Pediatric Immune Thrombocytopenia
HCPLive
DECEMBER 8, 2024
Data from the PINES trial at ASH 2024 suggest eltrombopag could outperform current standard of care for platelet response in newly diagnosed pediatric ITP.
Case Report: Concurrent transcatheter aortic and mitral valve replacement for symptomatic concomitant aortic and mitral valve stenoses
Frontiers in Cardiovascular Medicine
DECEMBER 8, 2024
In patients undergoing transcatheter aortic valve implantation (TAVI), multi-valve disease is common and associated with worse outcomes. Despite multiple emerging transcatheter valve treatment options, no guidelines exist for the transcatheter treatment of multi-valve disease. We present a case of a 76-year-old patient with concomitant severe aortic valve stenosis and severe mitral valve stenosis who underwent concurrent TAVI and transcatheter mitral valve replacement.
Early and Long-term Outcomes of Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention to the Left Main Coronary Artery
The American Journal of Cardiology
DECEMBER 8, 2024
Association of cardiovascular-kidney-metabolic index with all-cause mortality during hospitalization in critically ill patients: a retrospective cohort study from MIMIC IV2.2
Frontiers in Cardiovascular Medicine
DECEMBER 8, 2024
BackgroundThe cardiovascular-kidney-metabolic index (CKMI), a novel functional indicator proposed in this study, aims to accurately reflect the functional status of the heart, kidneys, and metabolism. However, its ability to predict mortality risk in critically ill patients during their stay in the intensive care unit (ICU) remains uncertain. Therefore, this study aims to validate the correlation between the CKMI during hospitalization and all-cause mortality.MethodsThe study utilized the Medica
I am a healthy man with an “Incidentally detected” 30% plaque in LAD by CT Angio : My cardiologist, Insists my target LDL should be 55 mg, Is he right ?
Dr. S. Venkatesan MD
DECEMBER 8, 2024
Fixing the target LDL, in both primary and secondary prevention is becoming more & more complex. The reason being, there is a huge healthy population ( with zero risk factor) , but showing insignificant or minimal coronary plaques. This subset of population is anxiously unmasked by inclusion of CT angiogram in many master health check-up programs.
Interleukin-6 and thyroid-stimulating hormone index predict plaque stability in carotid artery stenosis: analyses by lasso-logistic regression
Frontiers in Cardiovascular Medicine
DECEMBER 8, 2024
ObjectiveTo develop and validate a new prediction model based on the Lass-logistic regression with inflammatory serologic markers for the assessment of carotid plaque stability, providing clinicians with a reliable tool for risk stratification and decision-making in the management of carotid artery disease.MethodsIn this study, we retrospectively collected the data of the patients who underwent carotid endarterectomy (CEA) from 2019 to 2023 in Nanjing Drum Tower Hospital.
SMOC2, OGN, FCN3, and SERPINA3 could be biomarkers for the evaluation of acute decompensated heart failure caused by venous congestion
Frontiers in Cardiovascular Medicine
DECEMBER 8, 2024
BackgroundVenous congestion (VC) sets in weeks before visible clinical decompensation, progressively increasing cardiac strain and leading to acute heart failure (HF) decompensation. Currently, the field lacks a universally acknowledged gold standard and early detection methods for VC.MethodsUsing data from the GEO database, we identified VC's impact on HF through key genes using Limma and STRING databases.
Cerebrotendinous xanthomatosis: a literature review and case study
Frontiers in Cardiovascular Medicine
DECEMBER 8, 2024
Cerebrotendinous xanthomatosis (CTX) is a rare but treatable inherited neurometabolic disorder that can lead to severe sequelae if left untreated. Chenodeoxycholic acid is a safe and effective treatment for CTX. Early diagnosis is essential to improve patient outcomes. Neurological disturbances, cataracts, and intractable diarrhea are key features to raise diagnostic suspicion and differentiate CTX from other metabolic disorders in patients with dyslipidemia and xanthomas.
Endovascular intravascular intervention for central venous stenosis in maintenance hemodialysis patients: a retrospective observational study
Frontiers in Cardiovascular Medicine
DECEMBER 8, 2024
BackgroundThe number of people undergoing maintenance hemodialysis is increasing rapidly worldwide. Central vein stenosis (CVS) is a common vascular complication in undergoing hemodialysis, especially those with a history of catheterization. This study aimed to investigate the characteristics of CVS and the clinical effectiveness of percutaneous transluminal angioplasty (PTA) alone and sequential percutaneous transluminal stenting (PTS) in hemodialysis patients with CVS.MethodsA retrospective an
SGLT2 inhibitors for alleviating heart failure through non-hypoglycemic mechanisms
Frontiers in Cardiovascular Medicine
DECEMBER 8, 2024
Sodium-glucose cotransporter-2 (SGLT2) inhibitors afford significant cardiovascular benefits to patients with diabetes mellitus and heart failure. Three large randomized clinical trials (EMPAREG-Outcomes, DECLARE-TIMI58, and DAPA-HF) have shown that SGLT2 inhibitors prevent cardiovascular events and reduce the risk of death and hospital admission resulting from heart failure.
Let's personalize your content